Tumor Biology

, Volume 36, Issue 12, pp 9499–9510 | Cite as

Resveratrol induces AMPK-dependent MDR1 inhibition in colorectal cancer HCT116/L-OHP cells by preventing activation of NF-κB signaling and suppressing cAMP-responsive element transcriptional activity

Research Article


Resveratrol, a natural polyphenolic compound found in foods and beverages, has attracted increasing attention in recent years because of its potent chemopreventive and anti-tumor effects. In this study, the effects of resveratrol on the expression of P-glycoprotein/multi-drug resistance protein 1 (P-gp/MDR1), and the underlying molecular mechanisms, were investigated in oxaliplatin (L-OHP)-resistant colorectal cancer cells (HCT116/L-OHP). Resveratrol downregulated MDR1 protein and mRNA expression levels and reduced MDR1 promoter activity. It also enhanced the intracellular accumulation of rhodamine 123, suggesting that resveratrol can reverse multi-drug resistance by downregulating MDR1 expression and reducing drug efflux. Resveratrol treatment also reduced nuclear factor-κB (NF-κB) activity, reduced phosphorylation levels of IκBα, and reduced nuclear translocation of the NF-κB subunit p65. Moreover, downregulation of MDR1 expression and promoter activity was mediated by resveratrol-induced AMP-activated protein kinase (AMPK) phosphorylation. The inhibitory effects of resveratrol on MDR1 expression and cAMP-responsive element-binding protein (CREB) phosphorylation were reversed by AMPKα siRNA transfection. We found that the transcriptional activity of cAMP-responsive element (CRE) was inhibited by resveratrol. These results demonstrated that the inhibitory effects of resveratrol on MDR1 expression in HCT116/L-OHP cells were closely associated with the inhibition of NF-κB signaling and CREB activation in an AMPK-dependent manner.


Resveratrol Multi-drug resistance AMPKα Colorectal cancer 



This work was supported by the National Natural Science Foundation of China (No. 81473482), the Putuo District Committee of Science and Technology, Shanghai, China (No. 201102), and Xinglin Scholars of Shanghai University of Traditional Chinese Medicine. This research was also supported by the construct program of the key discipline of State Administration of Traditional Chinese Medicine of the People’s Republic of China.

Conflicts of interest



  1. 1.
    Stein WD. Kinetics of the multidrug transporter (p-glycoprotein) and its reversal. Physiol Rev. 1997;77:545–90.PubMedGoogle Scholar
  2. 2.
    Steinbach D, Legrand O. Abc transporters and drug resistance in leukemia: Was p-gp nothing but the first head of the hydra? Leukemia. 2007;21:1172–6.CrossRefPubMedGoogle Scholar
  3. 3.
    Bentires-Alj M, Barbu V, Fillet M, Chariot A, Relic B, Jacobs N, et al. Nf-kappab transcription factor induces drug resistance through mdr1 expression in cancer cells. Oncogene. 2003;22:90–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Baldwin Jr AS. Series introduction: the transcription factor nf-kappab and human disease. J Clin Invest. 2001;107:3–6.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Wu M, Lee H, Bellas RE, Schauer SL, Arsura M, Katz D, et al. Inhibition of nf-kappab/rel induces apoptosis of murine b cells. EMBO J. 1996;15:4682–90.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Cusack Jr JC, Liu R, Baldwin Jr AS. Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothe cin (cpt-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-kappab activation. Cancer Res. 2000;60:2323–30.PubMedGoogle Scholar
  7. 7.
    Um JH, Kang CD, Lee BG, Kim DW, Chung BS, Kim SH. Increased and correlated nuclear factor-kappa b and ku autoantigen activities are associated with development of multidrug resistance. Oncogene. 2001;20:6048–56.CrossRefPubMedGoogle Scholar
  8. 8.
    Kuo MT, Liu Z, Wei Y, Lin-Lee YC, Tatebe S, Mills GB, et al. Induction of human mdr1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate nf-kappab signaling. Oncogene. 2002;21:1945–54.CrossRefPubMedGoogle Scholar
  9. 9.
    Svensson RU, Shaw RJ. Cancer metabolism: tumour friend or foe. Nature. 2012;485:590–1.CrossRefPubMedGoogle Scholar
  10. 10.
    Luo Z, Zang M, Guo W. Ampk as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol. 2010;6:457–70.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Chen S, Xiao X, Feng X, Li W, Zhou N, Zheng L, et al. Resveratrol induces sirt1-dependent apoptosis in 3t3-l1 preadipocytes by activating ampk and suppressing akt activity and survivin expression. J Nutr Biochem. 2012;23:1100–12.CrossRefPubMedGoogle Scholar
  12. 12.
    Kim YM, Hwang JT, Kwak DW, Lee YK, Park OJ. Involvement of ampk signaling cascade in capsaicin-induced apoptosis of ht-29 colon cancer cells. Ann N Y Acad Sci. 2007;1095:496–503.CrossRefPubMedGoogle Scholar
  13. 13.
    Rohlff C, Glazer RI. Regulation of multidrug resistance through the camp and egf signalling pathways. Cell Signal. 1995;7:431–43.CrossRefPubMedGoogle Scholar
  14. 14.
    Scala S, Budillon A, Zhan Z, Cho-Chung YS, Jefferson J, Tsokos M, et al. Downregulation of mdr-1 expression by 8-cl-camp in multidrug resistant mcf-7 human breast cancer cells. J Clin Invest. 1995;96:1026–34.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Wartenberg M, Fischer K, Hescheler J, Sauer H. Redox regulation of p-glycoprotein-mediated multidrug resistance in multicellular prostate tumor spheroids. Int J Cancer. 2000;85:267–74.CrossRefPubMedGoogle Scholar
  16. 16.
    Ziemann C, Riecke A, Rudell G, Oetjen E, Steinfelder HJ, Lass C, et al. The role of prostaglandin e receptor-dependent signaling via camp in mdr1b gene activation in primary rat hepatocyte cultures. J Pharmacol Exp Ther. 2006;317:378–86.CrossRefPubMedGoogle Scholar
  17. 17.
    Walton KM, Rehfuss RP, Chrivia JC, Lochner JE, Goodman RH. A dominant repressor of cyclic adenosine 3′,5′-monophosphate (camp)-regulated enhancer-binding protein activity inhibits the camp-mediated induction of the somatostatin promoter in vivo. Mol Endocrinol. 1992;6:647–55.PubMedGoogle Scholar
  18. 18.
    Takata T, Motoo Y, Tomosugi N. Effect of Saikokeishito, a Kampo medicine, on hydrogen peroxide-induced premature senescence of normal human dermal fibroblasts. J Integr Med. 2014;12:495–503.CrossRefPubMedGoogle Scholar
  19. 19.
    Ling CQ, Yue XQ, Ling C. Three advantages of using traditional Chinese medicine to prevent and treat tumor. J Integr Med. 2014;12:331–5.CrossRefPubMedGoogle Scholar
  20. 20.
    Li Y, Fang H, Xu W. Recent advance in the research of flavonoids as anticancer agents. Mini Rev Med Chem. 2007;7:663–78.CrossRefPubMedGoogle Scholar
  21. 21.
    Sun C, Hu Y, Liu X, Wu T, Wang Y, He W, et al. Resveratrol downregulates the constitutional activation of nuclear factor-kappab in multiple myeloma cells, leading to suppression of proliferation and invasion, arrest of cell cycle, and induction of apoptosis. Cancer Genet Cytogenet. 2006;165:9–19.CrossRefPubMedGoogle Scholar
  22. 22.
    Kweon SH, Song JH, Kim TS. Resveratrol-mediated reversal of doxorubicin resistance in acute myeloid leukemia cells via downregulation of mrp1 expression. Biochem Biophys Res Commun. 2010;395:104–10.CrossRefPubMedGoogle Scholar
  23. 23.
    Quan F, Pan C, Ma Q, Zhang S, Yan L. Reversal effect of resveratrol on multidrug resistance in kbv200 cell line. Biomed Pharmacother. 2008;62:622–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Huang F, Wu XN, Chen J, Wang WX, Lu ZF. Resveratrol reverses multidrug resistance in human breast cancer doxorubicin-resistant cells. Exp Ther Med. 2014;7:1611–6.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Ren Z, Wang L, Cui J, Huoc Z, Xue J, Cui H, et al. Resveratrol inhibits nf-kb signaling through suppression of p65 and ikappab kinase activities. Die Pharmazie. 2013;68:689–94.PubMedGoogle Scholar
  26. 26.
    Wang Z, Liang X, Cheng Z, Xu Y, Yin P, Zhu H, et al. Induction of apoptosis and suppression of ercc1 expression by the potent amonafide analogue 8-c in human colorectal carcinoma cells. Anti-Cancer Drugs. 2013;24:355–65.CrossRefPubMedGoogle Scholar
  27. 27.
    Israf DA, Khaizurin TA, Syahida A, Lajis NH, Khozirah S. Cardamonin inhibits cox and inos expression via inhibition of p65nf-kappab nuclear translocation and ikappa-b phosphorylation in raw 264.7 macrophage cells. Mol Immunol. 2007;44:673–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Wang J, Wu A, Xu Y, Liu J, Qian X. M(2)-a induces apoptosis and g(2)-m arrest via inhibiting pi3k/akt pathway in hl60 cells. Cancer Lett. 2009;283:193–202.CrossRefPubMedGoogle Scholar
  29. 29.
    Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of atp-dependent transporters. Nat Rev Cancer. 2002;2:48–58.CrossRefPubMedGoogle Scholar
  30. 30.
    Shen K, Cui D, Sun L, Lu Y, Han M, Liu J. Inhibition of igf-ir increases chemosensitivity in human colorectal cancer cells through mrp-2 promoter suppression. J Cell Biochem. 2012;113:2086–97.CrossRefPubMedGoogle Scholar
  31. 31.
    Ludescher C, Thaler J, Drach D, Drach J, Spitaler M, Gattringer C, et al. Detection of activity of p-glycoprotein in human tumour samples using rhodamine 123. Br J Haematol. 1992;82:161–8.CrossRefPubMedGoogle Scholar
  32. 32.
    Deng L, Lin-Lee YC, Claret FX, Kuo MT. 2-acetylaminofluorene up-regulates rat mdr1b expression through generating reactive oxygen species that activate nf-kappa b pathway. J Biol Chem. 2001;276:413–20.CrossRefPubMedGoogle Scholar
  33. 33.
    Ros JE, Schuetz JD, Geuken M, Streetz K, Moshage H, Kuipers F, et al. Induction of mdr1b expression by tumor necrosis factor-alpha in rat liver cells is independent of p53 but requires nf-kappab signaling. Hepatology. 2001;33:1425–31.CrossRefPubMedGoogle Scholar
  34. 34.
    Karin M. How nf-kappab is activated: the role of the ikappab kinase (ikk) complex. Oncogene. 1999;18:6867–74.CrossRefPubMedGoogle Scholar
  35. 35.
    Horike N, Sakoda H, Kushiyama A, Ono H, Fujishiro M, Kamata H, et al. Amp-activated protein kinase activation increases phosphorylation of glycogen synthase kinase 3beta and thereby reduces camp-responsive element transcriptional activity and phosphoenolpyruvate carboxykinase c gene expression in the liver. J Biol Chem. 2008;283:33902–10.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Chung SY, Sung MK, Kim NH, Jang JO, Go EJ, Lee HJ. Inhibition of p-glycoprotein by natural products in human breast cancer cells. Arch Pharm Res. 2005;28:823–8.CrossRefPubMedGoogle Scholar
  37. 37.
    Ikegawa T, Ushigome F, Koyabu N, Morimoto S, Shoyama Y, Naito M, et al. Inhibition of p-glycoprotein by orange juice components, polymethoxyflavones in adriamycin-resistant human myelogenous leukemia (k562/adm) cells. Cancer Lett. 2000;160:21–8.CrossRefPubMedGoogle Scholar
  38. 38.
    Patanasethanont D, Nagai J, Matsuura C, Fukui K, Sutthanut K, Sripanidkulchai BO, et al. Modulation of function of multidrug resistance associated-proteins by Kaempferia parviflora extracts and their components. Eur J Pharmacol. 2007;566:67–74.CrossRefPubMedGoogle Scholar
  39. 39.
    Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 1997;275:218–20.CrossRefPubMedGoogle Scholar
  40. 40.
    Hwang JT, Kwak DW, Lin SK, Kim HM, Kim YM, Park OJ. Resveratrol induces apoptosis in chemoresistant cancer cells via modulation of ampk signaling pathway. Ann N Y Acad Sci. 2007;1095:441–8.CrossRefPubMedGoogle Scholar
  41. 41.
    Jazirehi AR, Bonavida B. Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin’s lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther. 2004;3:71–84.CrossRefPubMedGoogle Scholar
  42. 42.
    Ogura M, Takatori T, Tsuruo T. Purification and characterization of nf-r1 that regulates the expression of the human multidrug resistance (mdr1) gene. Nucleic Acids Res. 1992;20:5811–7.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Ogretmen B, Safa AR. Negative regulation of mdr1 promoter activity in mcf-7, but not in multidrug resistant mcf-7/adr, cells by cross-coupled nf-kappa b/p65 and c-fos transcription factors and their interaction with the caat region. Biochemistry. 1999;38:2189–99.CrossRefPubMedGoogle Scholar
  44. 44.
    Thevenod F, Friedmann JM, Katsen AD, Hauser IA. Up-regulation of multidrug resistance p-glycoprotein via nuclear factor-kappab activation protects kidney proximal tubule cells from cadmium- and reactive oxygen species-induced apoptosis. J Biol Chem. 2000;275:1887–96.CrossRefPubMedGoogle Scholar
  45. 45.
    Brown KA, Samarajeewa NU, Simpson ER. Endocrine-related cancers and the role of ampk. Mol Cell Endocrinol. 2013;366:170–9.CrossRefPubMedGoogle Scholar
  46. 46.
    Djouder N, Tuerk RD, Suter M, Salvioni P, Thali RF, Scholz R, et al. Pka phosphorylates and inactivates ampkalpha to promote efficient lipolysis. EMBO J. 2010;29:469–81.CrossRefPubMedGoogle Scholar
  47. 47.
    Parissenti AM, Gannon BR, Villeneuve DJ, Kirwan-rhude AF, Chadderton A, Gluck S. Lack of modulation of mdr1 gene expression by dominant inhibition of camp-dependent protein kinase in doxorubicin-resistant mcf-7 breast cancer cells. Int J Cancer. 1999;82:893–900.CrossRefPubMedGoogle Scholar
  48. 48.
    Delghandi MP, Johannessen M, Moens U. The camp signalling pathway activates creb through pka, p38 and msk1 in nih 3t3 cells. Cell Signal. 2005;17:1343–51.CrossRefPubMedGoogle Scholar
  49. 49.
    Yamagishi N, Nakao R, Kondo R, Nishitsuji M, Saito Y, Kuga T, et al. Increased expression of sorcin is associated with multidrug resistance in leukemia cells via up-regulation of mdr1 expression through camp response element-binding protein. Biochem Biophys Res Commun. 2014;448:430–6.CrossRefPubMedGoogle Scholar
  50. 50.
    Branvold DJ, Allred DR, Beckstead DJ, Kim HJ, Fillmore N, Condon BM, et al. Thyroid hormone effects on lkb1, mo25, phospho-ampk, phospho-creb, and pgc-1alpha in rat muscle. J Appl Physiol. 2008;105:1218–27.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Ziyuan Wang
    • 1
  • Long Zhang
    • 1
  • Zhenhua Ni
    • 1
  • Jian Sun
    • 1
  • Hong Gao
    • 1
  • Zhuoan Cheng
    • 1
  • Jianhua Xu
    • 1
    • 2
  • Peihao Yin
    • 1
  1. 1.Interventional Cancer Institute of Chinese Integrative Medicine, Putuo HospitalShanghai University of Traditional Chinese MedicineShanghaiChina
  2. 2.Department of Clinical Oncology, Putuo HospitalShanghai University of Traditional Chinese MedicineShanghaiChina

Personalised recommendations